Xanthine oxidase inhibitors are new class of compounds for the treatment of fibrotic diseases.In the present investigation, the effect of Xanthine Oxidase Inhibitor, Febuxostat was studied in experimental model of myocardial fibrosis. Myocardial fibrosis was induced by administration of isoproterenol (5 mg/kg i.p for 15 days). Febuxostat (5, 10, 15 mg/kg, p.o) was admimistered for 15 days in Isoproterenol treated groups of animals. The most widely accepted mechanism of myocardial toxicity is through generation of reactive oxygen species (ROS), which causes mitochondrial cell death. The cardiac functional measurements and the left and right ventricular weight indices (LVWI and RVWI respectively) were analyzed. Theadministration of Febuxostat resulted in significant improvement in cardiac function, decrease in cardiac weight indices, and reduced fibrous tissue proliferation with normalization of electrocardiographic measurement. Febuxostat treated group of animals also showed decrease in level of malondialdehyde with increase in level of defensive antioxidant enzymes (CAT, SOD, GSH). Thus Febuxostat exerts antioxidant activity against Isoproterenol induced myocardial fibrosis. The results obtained in this study provide evidence for the usefulness of Febuxostat as a cardio protective agent.